Edwards Lifesciences Corporation EW

Revenue Intelligence Report • 66 quarters of SEC filing data • Updated 2026-03-15

The revenue model shows SG&A spending has higher revenue elasticity than R&D, with a 1% increase in SG&A associated with a 1.22% revenue lift versus 0.80% for 1% R&D, indicating SG&A investments currently yield stronger revenue leverage. The 66-quarter log-log model delivers a 4.3% MAPE and, in a holdout test, predicted $1.6B against actual $1.6B with a -0.8% error, underscoring forecast reliability. The FY outlook calls for about $7.1B in revenue, up roughly 16.5% year over year, signaling solid top-line momentum. Investors should note that while SG&A offers greater revenue leverage than R&D, net ROI depends on margins and operating efficiency, but the overall outlook remains favorable given disciplined spending and strong growth trajectory.

Investment Thesis

The econometric model achieves strong accuracy (4.3% MAPE), suggesting Edwards Lifesciences Corporation's revenue trajectory is well-characterized by its spending patterns. R&D investment shows a 0.80x multiplier — each 1% increase in R&D spend is associated with a 0.80% revenue increase, signaling strong innovation-to-revenue conversion. Sales & marketing spend shows a 1.22x elasticity, suggesting effective go-to-market execution.

Next FY Revenue
$7.07B
+16.5% YoY
R&D Elasticity
0.80x
SG&A Elasticity
1.22x
Model Accuracy
4.3% MAPE
Holdout validation: The model predicted $1.6B vs the actual $1.6B — an error of 0.8%.

Revenue Forecast

EW Revenue Forecast

Quarterly Detail

QuarterModel ForecastActual95% RangeYoY GrowthStatus
Q4 2025 $1.6B $1.6B $1.4B – $1.8B +14.1% ✓ In range
Q2 2026 $1.7B $1.5B – $2.0B +20.0%
Q3 2026 $1.7B $1.4B – $2.1B +13.5%
Q4 2026 $1.8B $1.5B – $2.2B +16.1%
Q1 2027 $1.8B $1.4B – $2.3B +16.8%

Seasonal Factors

Multiplicative seasonal adjustment: These factors capture Edwards Lifesciences Corporation's systematic quarterly revenue patterns relative to the trend model. A factor of 1.05 means that quarter typically runs 5% above the underlying trend; 0.95 means 5% below. Factors are computed as the median of (actual / fitted) across all available quarters.
Fiscal QuarterSeasonal Factorvs TrendInterpretationObs.
FQ1 (Sep–Nov) 0.9725 -2.7% In line with trend 16
FQ2 (Dec–Feb) 1.0348 +3.5% +3.5% above trend 16
FQ3 (Mar–May) 1.0126 +1.3% In line with trend 15
FQ4 (Jun–Aug) 0.9967 -0.3% In line with trend 15

How Spending Drives Revenue

EW Spending Timing
Reading this chart: Each line shows the cumulative elasticity — how a 1% increase in spending translates to revenue growth over subsequent quarters. The effect builds over 4-5 quarters as investments compound.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch

Data sourced from SEC EDGAR XBRL filings. Model: ARDL (log-log) with 66 quarters. This analysis is for informational purposes only and does not constitute investment advice.

More in Healthcare

CNC MTD VRTX GEHC CI INCY A IQV